257 related articles for article (PubMed ID: 11822989)
1. Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies.
Paley PJ
Curr Oncol Rep; 2002 Mar; 4(2):165-74. PubMed ID: 11822989
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic treatment strategies for malignant brain tumors.
Kirsch M; Schackert G; Black PM
J Neurooncol; 2000; 50(1-2):149-63. PubMed ID: 11245274
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and cancer: recent advances.
Cáceres W; González S
P R Health Sci J; 2003 Jun; 22(2):149-51. PubMed ID: 12866139
[TBL] [Abstract][Full Text] [Related]
4. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.
Yokoyama Y; Dhanabal M; Griffioen AW; Sukhatme VP; Ramakrishnan S
Cancer Res; 2000 Apr; 60(8):2190-6. PubMed ID: 10786683
[TBL] [Abstract][Full Text] [Related]
5. [The clinical perspective of angiogenesis inhibitors].
Radema SA; Witteveen PO; Gebbink MB; Voest EE
Ned Tijdschr Geneeskd; 2003 Aug; 147(35):1675-80. PubMed ID: 14513538
[TBL] [Abstract][Full Text] [Related]
6. Role of angiogenesis in tumor growth and metastasis.
Folkman J
Semin Oncol; 2002 Dec; 29(6 Suppl 16):15-8. PubMed ID: 12516034
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
8. Are angiostatin and endostatin cures for cancer?
Harris AL
Lancet; 1998 May; 351(9116):1598-9. PubMed ID: 9620709
[No Abstract] [Full Text] [Related]
9. Angiogenesis and tumor metastasis.
Zetter BR
Annu Rev Med; 1998; 49():407-24. PubMed ID: 9509272
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors.
Puduvalli VK; Sawaya R
J Neurooncol; 2000; 50(1-2):189-200. PubMed ID: 11245279
[TBL] [Abstract][Full Text] [Related]
11. The promise of anti-angiogenic cancer therapy.
Oehler MK; Bicknell R
Br J Cancer; 2000 Feb; 82(4):749-52. PubMed ID: 10732738
[No Abstract] [Full Text] [Related]
12. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice.
Scappaticci FA; Smith R; Pathak A; Schloss D; Lum B; Cao Y; Johnson F; Engleman EG; Nolan GP
Mol Ther; 2001 Feb; 3(2):186-96. PubMed ID: 11237675
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic prospects of angiogenesis inhibitors in cancerology].
Bout JC; Soncin F; Vandenbunder B
Rev Mal Respir; 1999 Nov; 16(5):854-5. PubMed ID: 10612161
[No Abstract] [Full Text] [Related]
14. Cancer experts offer healthy dose of skepticism toward hype over antiangiogenesis agents.
Phillips P
JAMA; 1998 Jun; 279(24):1936-7. PubMed ID: 9643843
[No Abstract] [Full Text] [Related]
15. Molecular mechanisms of tumor angiogenesis and tumor progression.
Cavallaro U; Christofori G
J Neurooncol; 2000; 50(1-2):63-70. PubMed ID: 11245282
[TBL] [Abstract][Full Text] [Related]
16. Targeted anti-vascular therapies for ovarian cancer: current evidence.
Hall M; Gourley C; McNeish I; Ledermann J; Gore M; Jayson G; Perren T; Rustin G; Kaye S
Br J Cancer; 2013 Feb; 108(2):250-8. PubMed ID: 23385789
[TBL] [Abstract][Full Text] [Related]
17. Regulating angiogenesis: a new therapeutic strategy.
Gibaldi M
J Clin Pharmacol; 1998 Oct; 38(10):898-903. PubMed ID: 9807969
[TBL] [Abstract][Full Text] [Related]
18. Anticancer drug targets: approaching angiogenesis.
Keshet E; Ben-Sasson SA
J Clin Invest; 1999 Dec; 104(11):1497-501. PubMed ID: 10587512
[No Abstract] [Full Text] [Related]
19. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
20. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
